Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1968
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1972 4
1973 1
1974 5
1975 2
1977 1
1978 1
1979 3
1980 4
1981 5
1982 5
1983 5
1984 1
1985 2
1986 4
1987 4
1988 21
1989 6
1990 6
1991 13
1992 9
1993 11
1994 16
1995 16
1996 15
1997 11
1998 15
1999 20
2000 35
2001 25
2002 23
2003 16
2004 14
2005 18
2006 21
2007 23
2008 21
2009 24
2010 22
2011 20
2012 33
2013 28
2014 34
2015 35
2016 42
2017 47
2018 49
2019 51
2020 37
2021 51
2022 62
2023 62
2024 61
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

923 results

Results by year

Filters applied: . Clear all
Page 1
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Compared to placebo, mavacamte
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc
Cardiomyopathies: An Overview.
Ciarambino T, Menna G, Sansone G, Giordano M. Ciarambino T, et al. Int J Mol Sci. 2021 Jul 19;22(14):7722. doi: 10.3390/ijms22147722. Int J Mol Sci. 2021. PMID: 34299342 Free PMC article. Review.
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy (ARCV), takotsubo syndrome". RESULTS: Hypertrophic
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopath
Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Bishev D, et al. Heart Lung Circ. 2023 Sep;32(9):1049-1056. doi: 10.1016/j.hlc.2023.05.019. Epub 2023 Jul 14. Heart Lung Circ. 2023. PMID: 37453852 Free article. Review.
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats symptoms, mavacamten targets the underlying pathology. ...All four studies showed a reduction in NYHA class from mavacamten use. Three out of …
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats sy …
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215938 Free article. Review.
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting do …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorit …
New perspectives on the prevalence of hypertrophic cardiomyopathy.
Semsarian C, Ingles J, Maron MS, Maron BJ. Semsarian C, et al. J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254. doi: 10.1016/j.jacc.2015.01.019. J Am Coll Cardiol. 2015. PMID: 25814232 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which prevalence in the general population has not been completely resolved. For the past 20 years, most data have supported the occurrence of HCM at about 1 in 500. However, t
Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which prevalence in the general population
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS, El-Nakhal T, Hasabo EA, Shehata N, Wilson K, Ismail KH, Bakr MS, Mohsen M, Mohamed A, Abdelazim E, Ali HT, Soliman Z, Sayed A, Abdelsayed K, Caliskan K, Soliman O. Yacoub MS, et al. Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19. Heart Fail Rev. 2024. PMID: 38112937 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistically significant increase in the frequency of the primary composite endpoint (RR = 1.92, 95% CI [1.28, 2.88]), 1 NYHA c
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistic
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management.
Lioncino M, Monda E, Verrillo F, Moscarella E, Calcagni G, Drago F, Marino B, Digilio MC, Putotto C, Calabrò P, Russo MG, Roberts AE, Gelb BD, Tartaglia M, Limongelli G. Lioncino M, et al. Heart Fail Clin. 2022 Jan;18(1):19-29. doi: 10.1016/j.hfc.2021.07.004. Epub 2021 Oct 25. Heart Fail Clin. 2022. PMID: 34776080 Free PMC article. Review.
Diagnosis of RASopathy can be triggered by clinical clues ("red flags") which may direct the clinician toward a specific gene test. Compared with sarcomeric hypertrophic cardiomyopathy, hypertrophic cardiomyopathy in RASopathies (R-HCM) is associated w …
Diagnosis of RASopathy can be triggered by clinical clues ("red flags") which may direct the clinician toward a specific gene test. Compared …
Cardiology: hypertrophic cardiomyopathy.
Medical Masterclass contributors; Firth J. Medical Masterclass contributors, et al. Clin Med (Lond). 2019 Jan;19(1):61-63. doi: 10.7861/clinmedicine.19-1-61. Clin Med (Lond). 2019. PMID: 30651247 Free PMC article. Review. No abstract available.
Hypertrophic Cardiomyopathy: A Brief Overview.
Braunwald E. Braunwald E. Am J Cardiol. 2024 Feb 1;212S:S1-S3. doi: 10.1016/j.amjcard.2023.10.075. Epub 2024 Jan 29. Am J Cardiol. 2024. PMID: 38368032 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a complex, heterogeneous disorder that affects approximately 1 in every 500 persons worldwide and about 750,000 Americans. ...
Hypertrophic cardiomyopathy (HCM) is a complex, heterogeneous disorder that affects approximately 1 in every 500 person
923 results